Website
News25/Ratings2
News · 26 weeks26-50%
2025-10-262026-04-19
Mix1490d
- Insider8(57%)
- Other3(21%)
- SEC Filings3(21%)
Latest news
25 items- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, a
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough ModelAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. "These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM," said Tim Dyer, CEO of Addex. "Chronic cough is a
- INSIDERSEC Form 3 filed by new insider Mills Roger3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawton Vincent Michael3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Teyssedou Lenaic Nathanael3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kalinichev Mikhail3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hill Raymond George3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dyer Timothy Mark3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nunn Jason Raleigh3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Manke Isaac3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder TreatmentData published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for SchizophreniaAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. "The progression
- PRAddex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright & Co.") initially entered into on January 30, 2024. The at-the-market offering program enables Addex to offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $3.3 million through H.C. Wainwright & Co., as its sales agent. T
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form 424B5 filed by Addex Therapeutics Ltd424B5 - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form EFFECT filed by Addex Therapeutics LtdEFFECT - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate UpdateAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro
- PRAddex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025 Title: Addex Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Upd
- SECSEC Form F-3 filed by Addex Therapeutics LtdF-3 - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)